EUROFINS SCIENTIFIC

May 26, 2008

Eurofins has pleasure in announcing the doubling in size of its laboratories in Nantes, making it the biggest investment project by Eurofins in France to date and also the most significant investment sum that the Group has made in France excluding acquisitions. The inauguration of the new facilities takes place today, Monday 26th May, in conjunction with the launching of “Generation Atlanpole”, the public organisation in charge of developing the technological development and commercial attractiveness of the city of Nantes and the Pays de la Loire region.

Eurofins Nantes has invested heavily in the last 10 years in new analytical technologies and in the development of better responses to the demands of its clients and to respond to the succession of food and feed crises that have taken place in that period. With around 250 employees and in expectation of carrying our more than 200,000 tests in 2008, the Nantes site has doubled in size, from 4,500 m² to more than 9,000 m², through an investment in buildings of more than €6.5m and an operational investment programme, such as customized layout, materials and analysis equipment, of €1m per year over the next five years.

Within the framework of this investment:•Eurofins Nantes will become the operational headquarters of the Eurofins Group in France,•A new laboratory for sensory evaluation will be developed, in order to increase the geographic coverage of the Eurofins Marketing Research business.•As a result of the success of the French Institute for Genetic

Fingerprinting, the space dedicated to this activity will be more than doubled.As a result of the combination and expansion of chemistry and bio-analysis capabilities, a new laboratory for sensory evaluation has been created at the Nantes site. Complementing the existing Eurofins Marketing Research facilities at Paris, Evry, Aix-en-Provence and Caen this new site will expand the geographic network in the west of the country and position Eurofins Marketing Research as the provider offering the largest sensory testing capacity in France. A true analytical test, sensory evaluation has become a key tool for R&D and Quality departments, particularly in agro-food enterprises that wish to measure the qualities perceived by consumers. This new laboratory is equipped with 32 evaluation booths, a dedicated testing room and a visual-reaction room that will support the approach of Eurofins Marketing Research in its work in product testing globally.

Born from the desire of the Eurofins Group to create a European forensic network, the French Institute for Genetic Fingerprinting (IFEG) was started in 2005 with just one expert. Today the company has been strengthened by the addition of six experts (of which two are accredited by the Court of Final Appeal) supported by a team of around 30 people who are available around the clock to carry out genetic fingerprinting as part of judicial investigations throughout France.

The Nantes facility will provide a dual role of co-ordination of activities and the production of analyses as the reference laboratory of the Group in performing the most complex and delicate tests. The construction of the new space of 500 m² for IFEG at Nantes is in response to the need for an increase in capacity. IFEG is at the heart of a European network of genetic laboratories that is being developed by Eurofins in Munich, Paris, Aix-en-Provence and Illkirch.

• This is an abridged version of the full French press release. For the extended version (in French) please visit: http://www.eurofins.fr/informations-financieres/communiques-de-presse.aspx

For more information about this press release or the Eurofins Group, please visit www.eurofins.com or contact:

François Vigneau, Directeur général Jean-Marc Le Gall, Directeur général Eurofins Food France and IFEGEurofins Marketing ResearchTél : +33-2 51 83 21 00 Tél : +33-1 53 34 17 47Email: Eurofinsfr@eurofins.com Email: JeanMarcLeGall@eurofins.com

Investor RelationsTél.:+32-2-769 7383E-mail: ir@eurofins.com

Notes for the editor:Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.